KPRX
Price
$2.75
Change
-$0.06 (-2.14%)
Updated
Oct 3 closing price
Capitalization
9.44M
SYRE
Price
$15.89
Change
-$0.09 (-0.56%)
Updated
Oct 3 closing price
Capitalization
959.77M
32 days until earnings call
Interact to see
Advertisement

KPRX vs SYRE

Header iconKPRX vs SYRE Comparison
Open Charts KPRX vs SYREBanner chart's image
Kiora Pharmaceuticals
Price$2.75
Change-$0.06 (-2.14%)
Volume$36.23K
Capitalization9.44M
Spyre Therapeutics
Price$15.89
Change-$0.09 (-0.56%)
Volume$430.49K
Capitalization959.77M
KPRX vs SYRE Comparison Chart in %
KPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KPRX vs. SYRE commentary
Oct 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KPRX is a Hold and SYRE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 05, 2025
Stock price -- (KPRX: $2.75 vs. SYRE: $15.89)
Brand notoriety: KPRX and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KPRX: 64% vs. SYRE: 77%
Market capitalization -- KPRX: $9.44M vs. SYRE: $959.77M
KPRX [@Biotechnology] is valued at $9.44M. SYRE’s [@Biotechnology] market capitalization is $959.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $103.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KPRX’s FA Score shows that 2 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • KPRX’s FA Score: 2 green, 3 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, KPRX is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KPRX’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • KPRX’s TA Score: 5 bullish, 4 bearish.
  • SYRE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, KPRX is a better buy in the short-term than SYRE.

Price Growth

KPRX (@Biotechnology) experienced а +5.36% price change this week, while SYRE (@Biotechnology) price change was -2.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.93%. For the same industry, the average monthly price growth was +13.10%, and the average quarterly price growth was +80.18%.

Reported Earning Dates

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+4.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($960M) has a higher market cap than KPRX($9.44M). KPRX has higher P/E ratio than SYRE: KPRX (3.67) vs SYRE (1.72). KPRX YTD gains are higher at: -16.667 vs. SYRE (-31.744). KPRX has higher annual earnings (EBITDA): -9.41M vs. SYRE (-222.15M). SYRE has more cash in the bank: 527M vs. KPRX (20.7M). SYRE has less debt than KPRX: SYRE (0) vs KPRX (430K). KPRX (0) and SYRE (0) have equivalent revenues.
KPRXSYREKPRX / SYRE
Capitalization9.44M960M1%
EBITDA-9.41M-222.15M4%
Gain YTD-16.667-31.74453%
P/E Ratio3.671.72214%
Revenue00-
Total Cash20.7M527M4%
Total Debt430K0-
FUNDAMENTALS RATINGS
KPRX vs SYRE: Fundamental Ratings
KPRX
SYRE
OUTLOOK RATING
1..100
919
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
66
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
6161
P/E GROWTH RATING
1..100
183
SEASONALITY SCORE
1..100
5036

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KPRX's Valuation (33) in the Pharmaceuticals Other industry is somewhat better than the same rating for SYRE (66) in the Pharmaceuticals Major industry. This means that KPRX’s stock grew somewhat faster than SYRE’s over the last 12 months.

KPRX's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that KPRX’s stock grew similarly to SYRE’s over the last 12 months.

KPRX's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as SYRE (98) in the Pharmaceuticals Major industry. This means that KPRX’s stock grew similarly to SYRE’s over the last 12 months.

KPRX's Price Growth Rating (61) in the Pharmaceuticals Other industry is in the same range as SYRE (61) in the Pharmaceuticals Major industry. This means that KPRX’s stock grew similarly to SYRE’s over the last 12 months.

KPRX's P/E Growth Rating (1) in the Pharmaceuticals Other industry is significantly better than the same rating for SYRE (83) in the Pharmaceuticals Major industry. This means that KPRX’s stock grew significantly faster than SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KPRXSYRE
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 6 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
88%
Aroon
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
KPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MNPR99.392.18
+2.24%
Monopar Therapeutics Inc
SPRO2.050.02
+0.99%
Spero Therapeutics
SUPN48.350.39
+0.81%
Supernus Pharmaceuticals
SNA347.42-1.71
-0.49%
Snap-on
ERNA1.20-0.02
-1.65%
Ernexa Therapeutics Inc

KPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, KPRX has been loosely correlated with CGEN. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if KPRX jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KPRX
1D Price
Change %
KPRX100%
-2.14%
CGEN - KPRX
33%
Loosely correlated
-7.39%
ELVN - KPRX
32%
Poorly correlated
-1.56%
SYRE - KPRX
32%
Poorly correlated
-0.56%
ABVX - KPRX
31%
Poorly correlated
+1.27%
VRDN - KPRX
31%
Poorly correlated
+2.03%
More